Oxidative stress and neurodegenerative disorders

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 24438-24475

  Li, Jie ^a   Wuliji, O ^b   Li, Wei ^a   Jiang, Zhi Gang ^c   Ghanbari, Hossein A ^c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b INNER MONGOLIA UNIVERSITY FOR NATIONALITIES   (China)

^c Panacea Pharmaceuticals Inc   (United States)

Author keywords

Aging; Chemobrain; Neurodegenerative diseases; Neurotoxicants; Oxidative stress; Peripheral neuropathy; Pharmaceutical; Signal transduction

Indexed keywords

1, 1 DIPHENYL 2 PICRYLHYDRAZYL; ACTIVATING TRANSCRIPTION FACTOR 6; ALTRETAMINE; BORTEZOMIB; CARBOPLATIN; CATALASE; CISPLATIN; CYTARABINE; CYTOCHROME P450; DOCETAXEL; FLUOROURACIL; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IFOSFAMIDE; IXABEPILONE; LEVAMISOLE; METHOTREXATE; MIRTAZAPINE; NEUROPROTECTIVE AGENT; OXALIPLATIN; PACLITAXEL; PROCARBAZINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY; DEGENERATIVE DISEASE; DNA DAMAGE; ELECTRON SPIN RESONANCE; HUMAN; NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; ENDOPLASMIC RETICULUM STRESS; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; OXIDOREDUCTASES; REACTIVE OXYGEN SPECIES; UNFOLDED PROTEIN RESPONSE;

EID: 84890535338     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141224438     Document Type: Article

References (237)

1. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552, 335-344.
2. Coon, M.J.; Ding, X.; Pernecky, S.J.; Vaz, A.D.N. Cytochrome P450: Progress and predictions. FASEB J. 1992, 6, 669-673.
3. Reed, J.R.; Backes, W.L. Formation of P450·P450 complexes and their effect on P450 function. Pharmacol. Ther. 2012, 133, 299-310.
4. DeLeo, F.R.; Quinn, M.T. Assembly of the phagocyte NADPH oxidase: Molecular interaction of oxidase proteins. J. Leukoc. Biol. 1996, 60, 677-691.
5. Finkel, T. Redox-dependent signal transduction. FEBS Lett. 2000, 476, 52-54.
6. Gandhi, S.; Abramov, A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012, 2012, 428010.
7. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979, 59, 527-605.
8. Packer, M.A.; Porteous, C.M.; Murphy, M.P. Superoxide production by mitochondria in the presence of nitric oxide forms peroxynitrite. Biochem. Mol. Biol. Int. 1996, 40, 527-534.
9. Bringold, U.; Ghafourifar, P.; Richter, C. Peroxynitrite formed by mitochondrial NO synthase promotes mitochondrial Ca2+ release. Free Radic. Biol. Med. 2000, 29, 343-348.
10. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39, 44-84.
11. Stanley, B.A.; Sivakumaran, V.; Shi, S.; McDonald, I.; Lloyd, D.; Watson, W.H.; Aon, M.A.; Paolocci, N. Thioredoxin reductase-2 is essential for keeping low levels of H2O2 emission from isolated heart mitochondria. J. Biol. Chem. 2011, 286, 33669-33677.
12. Lu, J.; Holmgren, A. The thioredoxin antioxidant system. Free Radic. Biol. Med. 2013, doi:10.1016/j.freeradbiomed.2013.07.036.
13. Massaad, C.A.; Klann, E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid. Redox Signal. 2011, 14, 2013-2054.
14. Rao, R.K.; Clayton, L.W. Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. Biochem. Biophys. Res. Commun. 2002, 293, 610-616.
15. O'Loghlen, A.; Pérez-Morgado, M.I.; Salinas, M.; Martín, M.E. Reversible inhibition of the protein phosphatase 1 by hydrogen peroxide. Potential regulation of eIF2 alpha phosphorylation in differentiated PC12 cells. Arch. Biochem. Biophys. 2003, 417, 194-202.
16. Groeger, G.; Quiney, C.; Cotter, T.G. Hydrogen peroxide as a cell-survival signaling molecule. Antioxid. Redox Signal. 2009, 11, 2655-2671.
17. Gamou, S.; Shimizu, N. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett. 1995, 357, 161-164.
18. Goldkorn, T.; Balaban, N.; Matsukuma, K.; Chea, V.; Gould, R.; Last, J.; Chan, C.; Chavez, C. EGF-Receptor phosphorylation and signaling are targeted by H2O2 redox stress. Am. J. Respir. Cell. Mol. Biol. 1998, 19, 786-798.
19. Catarzi, S.; Romagnoli, C.; Marcucci, G.; Favilli, F.; Iantomasi, T.; Vincenzini, M.T. Redox regulation of ERK1/2 activation induced by sphingosine 1-phosphate in fibroblasts: Involvement of NADPH oxidase and platelet-derived growth factor receptor. Biochim. Biophys. Acta 2011, 1810, 446-456.
20. McCubrey, J.A.; LaHair, M.M.; Franklin, R.A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 2006, 8, 1775-1789.
21. Whisler, R.L.; Goyette, M.A.; Grants, I.S.; Newhouse, Y.G. Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. Arch. Biochem. Biophys. 1995, 319, 23-25.
22. Brookmeyer, R.; Gray, S.; Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 1998, 88, 1337-1342.
23. Choi, T.G.; Lee, J.; Ha, J.; Kim, S.S. Apoptosis signal-regulating kinase 1 is an intracellular inducer of p38 MAPK-mediated myogenic signalling in cardiac myoblasts. Biochim. Biophys. Acta 2011, 1813, 1412-1421.
24. Zhou, Y.; Yan, H.; Guo, M.; Zhu, J.; Xiao, Q.; Zhang, L. Reactive oxygen species in vascular formation and development. Oxid. Med. Cell. Longev. 2013, 2013, 374963.
25. Keisari, Y.; Braun, L.; Flescher, E. The oxidative burst and related phenomena in mouse macrophages elicited by different sterile inflammatory stimuli. Immunobiology 1983, 165, 78-89.
26. Weisskopf, M.G.; Castillo, P.E.; Zalutsky, R.A.; Nicoll, R.A. Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP. Science 1994, 265, 1878-1882.
27. Ito, M. Long term depression. Ann. Rev. Neurosci. 1989, 12, 85-102.
28. Mulkey, R.M.; Malenka, R.C. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron 1992, 9, 967-975.
29. Villers, A.; Godaux, E.; Ris, L. Long-lasting LTP requires neither repeated trains for its induction nor protein synthesis for its development. PLoS One 2012, 7, e40823.
30. Lau, C.G.; Takeuchi, K.; Rodenas-Ruano, A.; Takayasu, Y.; Murphy, J.; Bennett, M.V.; Zukin, R.S. Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity. Biochem. Soc. Trans. 2009, 37, 1369-1374.
31. Kiritoshi, T.; Ikeda, H.; Murase, K. Long-term potentiation of neuronal excitation in the central nucleus of the rat amygdala revealed by imaging with a voltage-sensitive dye. Brain Res. 2010, 1349, 32-40.
32. Klann, E.; Chen, S.-J.; Sweatt, J.D. Persistent protein kinase activation in the maintenance phase of long-term potentiation. J. Biol. Chem. 1991, 266, 24253-24256.
33. Klann, E.; Chen, S.-J.; Sweatt, J.D. Mechanism of protein kinase C activation during the induction and maintenance of long-term potentiation probed using a novel peptide substrate. Proc. Natl. Acad. Sci. USA 1993, 90, 8337-8341.
34. Sacktor, T.C.; Osten, P.; Valsamis, H.; Jiang, X.; Naik, M.U.; Sublette, E. Persistent activation of the ζ isoform of proten kinase C in the maintenance of long-term potentiation. Proc. Natl. Acad. Sci. USA 1993, 90, 8342-8346.
35. Fukanaga, K.; Stoppini, L.; Miyamoto, E.; Muller, D. Long-term potentiation is associated with an increased activity of Ca2+/calmodulindependent protein kinase II. J. Biol. Chem. 1993, 268, 7863-7867.
36. Barria, A.; Muller, D.; Derkach, V.; Griffith, L.C.; Soderling, T.R. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science 1997, 276, 2042-2045.
37. Ouyang, Y.; Kantor, D.; Harris, K.M.; Schuman, E.M.; Kennedy, M.B. Visualization of the distribution of autophosphorylated calcium/calmodulin-dependent protein kinase II after tetanic stimulation in the CA1 area of the hippocampus. J. Neurosci. 1997, 17, 5416-5427.
38. Blitzer, R.D.; Connor, J.H.; Brown, G.P.; Wong, T.; Shenolikar, S.; Iyengar, R.; Landau, E.M. Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP. Science 1998, 280, 1940-1942.
39. Malenka, R.C.; Bear, M.F. LTP and LTD: An embarrassment of riches. Neuron 2004, 44, 5-21.
40. Serrano, P.; Yao, Y.; Sacktor, T. Persistent phosphorylation by protein kinase Mzeta maintains late-phase long-term potentiation. J. Neurosci. 2005, 25, 1979-1984.
41. Pastalkova, E.; Serrano, P.; Pinkhasova, D.; Wallace, E.; Fenton, A.; Sacktor, T. Storage of spatial information by the maintenance mechanism of LTP. Science 2006, 313, 1141-1144.
42. Anwyl, R. Metabotropic glutamate receptor-dependent long-term potentiation. Neuropharmacology 2009, 56, 735-740.
43. Skeberdis, V.A.; Lan, J.; Opitz, T.; Zheng, X.; Bennett, M.V.; Zukin, R.S. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology 2001, 40, 856-865.
44. Bindokas, V.P.; Jordan, J.; Lee, C.C.; Miller, R.J. Superoxide production in rat hippocampal neurons: Selective imaging with hydroethidine. J. Neurosci. 1996, 16, 1324-1336.
45. Klann, E. Cell-permeable scavengers of superoxide prevent long-term potentiation in hippocampal area CA1. J. Neurophysiol. 1998, 80, 452-457.
46. Kishida, K.T.; Hoeffer, C.A.; Hu, D.; Pao, M.; Holland, S.M.; Klann, E. Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. Mol. Cell. Biol. 2006, 26, 5908-5920.
47. Klann, E.; Roberson, E.D.; Knapp, L.T.; Sweatt, J.D. A role for superoxide in protein kinase C activation and the induction of long-term potentiation. J. Biol. Chem. 1998, 273, 4516-4522.
48. Klann, E.; Thiels, E. Modulation of protein kinases and protein phosphatases by reactive oxygen species: Implications for hippocampal synaptic plasticity. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999, 23, 359-376.
49. Knapp, L.T.; Klann, E. Potentiation of hippocampal synaptic transmission by superoxide requires the oxidative activation of protein kinase C. J. Neurosci. 2002, 22, 674-683.
50. Huddleston, A.T.; Tang, W.; Takeshima, H.; Hamilton, S.L.; Klann, E. Superoxide-induced potentiation in the hippocampus requires activation of ryanodine receptor type 3 and ERK. J. Neurophysiol. 2008, 99, 1565-1571.
51. Perry, T.L.; Godin, D.V.; Hansen, S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett. 1982, 33, 305-310.
52. Sian, J.; Dexter, D.T.; Lees, A.J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36, 348-355.
53. Townsend, D.M.; Tew, K.D.; Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57, 145-155.
54. Lü, J.M.; Lin, P.H.; Yao, Q.; Chen, C. Chemical and molecular mechanisms of antioxidants: Experimental approaches and model systems. J. Cell. Mol. Med. 2010, 14, 840-860.
55. Dizdaroglu, M. Quantitative determination of oxidative base damage in DNA by stable isotope-dilution mass spectrometry. FEBS Lett. 1993, 315, 1-6.
56. Cooke, M.S.; Olinski, R.; Evans, M.D. Does measurement of oxidative damage to DNA have clinical significance? Clin. Chim. Acta 2006, 365, 30-49.
57. Hu, J.; de Souza-Pinto, N.C.; Haraguchi, K.; Hogue, B.A.; Jaruga, P.; Greenberg, M.M.; Dizdaroglu, M.; Bohr, V.A. Repair of formamidopyrimidines in DNA involves different glycosylases: Role of the OGG1, NTH1, and NEIL1 enzymes. J. Biol. Chem. 2005, 280, 40544-40551.
58. Castellani, R.J.; Nunomura, A.; Rolston, R.K.; Moreira, P.I.; Takeda, A.; Perry, G.; Smith, M.A. Sublethal RNA oxidation as a mechanism for neurodegenerative disease. Int. J. Mol. Sci. 2008, 9, 789-806.
59. Katzman, R. Alzheimer's disease. N. Engl. J. Med. 1986, 314, 964-973.
60. Smith, M.A. Alzheimer's disease. Int. Rev. Neurobiol. 1998, 42, 1-54.
61. The World Health Report 2000-Health systems: Improving performance. Available online: http://www.who.int/whr/2000/en/ (accessed on 8 January 2009).
62. Obeso, J.A.; Rodríguez-Oroz, M.C.; Benitez-Temino, B.; Blesa, F.J.; Guridi, J.; Marin, C.; Rodriguez, M. Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease. Mov. Disord. 2008, 3, S548-S559.
63. Aylward, E.H.; Sparks, B.F.; Field, K.M.; Yallapragada, V.; Shpritz, B.D.; Rosenblatt, A.; Brandt, J.; Gourley, L.M.; Liang, K.; Zhou, H.; et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63, 66-72.
64. Kipps, C.M.; Duggins, A.J.; Mahant, N.; Gomes, L.; Ashburner, J.; McCusker, E.A. Progression of structural neuropathology in preclinical Huntington's disease: A tensor based morphometry study. J. Neurol. Neurosurg. Psychiatry 2005, 76, 650-655.
65. Neymotin, A.; Petri, S.; Calingasan, N.Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M.F.; Kiaei, M. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2009, 220, 191-197.
66. Hashimoto, M.; Rockenstein, E.; Crews, L.; Masliah, E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromol. Med. 2003, 4, 21-36.
67. Priller, C.; Bauer, T.; Mitteregger, G.; Krebs, B.; Kretzschmar, H.A.; Herms, J. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 2006, 26, 7212-7221.
68. Turner, P.R.; O'Connor, K.; Tate, W.P.; Abraham, W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 2003, 70, 1-32.
69. Hooper, N.M. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem. Soc. Trans. 2005, 33, 335-338.
70. Tiraboschi, P.; Hansen, L.A.; Thal, L.J.; Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004, 62, 1984-1989.
71. Ohnishi, S.; Takano, K. Amyloid fibrils from the viewpoint of protein folding. Cell. Mol. Life Sci. 2004, 61, 511-524.
72. Xiang, W.; Schlachetzki, J.C.; Helling, S.; Bussmann, J.C.; Berlinghof, M.; Schäffer, T.E.; Marcus, K.; Winkler, J.; Klucken, J.; Becker, C.M. Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol. Cell. Neurosci. 2013, 54, 71-83.
73. Zhou, M.; Xu, S.; Mi, J.; Uéda, K.; Chan, P. Nuclear translocation of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative stress. Brain Res. 2013, 1500, 19-27.
74. De Vos, K.J.; Grierson, A.J.; Ackerley, S.; Miller, C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008, 31, 151-173.
75. Deng, H.X.; Chen, W.; Hong, S.T.; Boycott, K.M.; Gorrie, G.H.; Siddique, N.; Yang, Y.; Fecto, F.; Shi, Y.; Zhai, H.; et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477, 211-215.
76. Su, B.; Wang, X.; Lee, H.G.; Tabaton, M.; Perry, G.; Smith, M.A.; Zhu, X. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci. Lett. 2010, 468, 267-271.
77. Gómez-Ramos, A.; Díaz-Nido, J.; Smith, M.A.; Perry, G.; Avila, J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J. Neurosci. Res. 2003, 71, 863-870.
78. Perez, M.; Cuadros, R.; Smith, M.A.; Perry, G.; Avila, J. Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett. 2000, 486, 270-274.
79. Wataya, T.; Nunomura, A.; Smith, M.A.; Siedlak, S.L.; Harris, P.L.R.; Shimohama, S.; Szweda, L.I.; Kaminski, M.A.; Avila, J.; Price, D.L.; et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J. Biol. Chem. 2002, 277, 4644-4648.
80. Liu, Q.; Smith, M.A.; Avilá, J.; DeBernardis, J.; Kansal, M.; Takeda, A.; Zhu, X.; Nunomura, A.; Honda, K.; Moreira, P.I.; et al. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic. Biol. Med. 2005, 38, 746-754.
81. Misonou, H.; Morishima-Kawashima, M.; Ihara, Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 2000, 39, 6951-6959.
82. Gabuzda, D.; Busciglio, J.; Chen, L.B.; Matsudaira, P.; Yankner, B.A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 1994, 269, 13623-13628.
83. Apelt, J.; Bigl, M.; Wunderlich, P.; Schliebs, R. Agingrelated increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimerlike pathology. Int. J. Dev. Neurosci. 2004, 22, 475-484.
84. Ghiso, J.; Frangione, B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. J. Alzheimers Dis. 2001, 3, 65-73.
85. Coma, M.; Guix, F.X.; Ill-Raga, G.; Uribesalgo, I.;, Alameda, F.; Valverde, M.A.; Muñoz, F.J. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol. Aging 2008, 29, 969-980.
86. Nekooki-Machida, Y.; Kurosawa, M.; Nukina, N.; Ito, K.; Oda, T.; Tanaka, M. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. USA 2009, 106, 9679-9684.
87. Mitomi, Y.; Nomura, T.; Kurosawa, M.; Nukina, N.; Furukawa, Y. Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates. J. Biol. Chem. 2012, 287, 34764-34775.
88. Goswami, A.; Dikshit, P.; Mishra, A.; Mulherkar, S.; Nukina, N.; Jana, N.R. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun. 2006, 342, 184-190.
89. Sorolla, M.A.; Reverter-Branchat, G.; Tamarit, J.; Ferrer, I.; Ros, J.; Cabiscol, E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 2008, 45, 667-678.
90. Cohen, T.J.; Hwang, A.W.; Unger, T.; Trojanowski, J.Q.; Lee, V.M. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J. 2012, 31, 1241-1252.
91. Chang, C.K.; Chiang, M.H.; Toh, E.K.; Chang, C.F.; Huang, T.H. Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS Lett. 2013, 587, 575-582.
92. Behl, C.; Davies, J.B.; Lesley, R.; Schubert, D. Hydrogen peroxide mediates amyloid protein toxicity. Cell 1994, 77, 817-827.
93. Bush, A.I.; Masters, C.L.; Tanzi, R.E. Copper, beta-amyloid, and Alzheimer's disease: Tapping a sensitive connection. Proc. Natl. Acad. Sci. USA 2003, 100, 11193-11194.
94. Behl, C.; Moosmann, B. Oxidative nerve cell death in Alzheimer's disease and stroke: Antioxidants as neuroprotective compounds. Biol. Chem. 2002, 383, 521-536.
95. Lynch, T.; Cherny, R.A.; Bush, A.I. Oxidative processes in Alzheimer's disease: The role of abeta-metal interactions. Exp. Gerontol. 2000, 35, 445-451.
96. Mark, R.J.; Hensley, K.; Butterfield, D.A.; Mattson, M.P. Amyloid beta-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J. Neurosci. 1995, 15, 6239-6249.
97. Mattson, M.P.; Chan, S.L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 2003, 34, 385-397.
98. Kawahara, M.; Kuroda, Y. Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: Channel formation and disruption of calcium homeostasis. Brain Res. Bull. 2000, 53, 389-397.
99. Kagan, B.L.; Hirakura, Y.; Azimov, R.; Azimova, R.; Lin, M.C. The channel hypothesis of Alzheimer's disease: Current status. Peptides 2002, 23, 1311-1315.
100. Ma, T.; Hoeffer, C.A.; Wong, H.; Massaad, C.A.; Zhou, P.; Iadecola, C.; Murphy, M.P.; Pautler, R.G.; Klann, E. Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci. 2011, 31, 5589-5595.
101. Dumont, M.; Wille, E.; Stack, C.; Calingasan, N.Y.; Beal, M.F.; Lin, M.T. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 2009, 23, 2459-2466.
102. Massaad, C.A.; Washington, T.M.; Pautler, R.G.; Klann, E. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2009, 106, 13576-13581.
103. Pitts, A.; Dailey, K.; Newington, J.T.; Chien, A.; Arseneault, R.; Cann, T.; Thompson, L.M.; Cumming, R.C. Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin. J. Biol. Chem. 2012, 287, 22717-22729.
104. Braun, R.J.; Sommer, C.; Carmona-Gutierrez, D.; Khoury, C.M.; Ring, J.; Büttner, S.; Madeo, F. Neurotoxic 43-kDa TAR DNA-binding protein (TDP-43) triggers mitochondrion-dependent programmed cell death in yeast. J. Biol. Chem. 2011, 286, 19958-19972.
105. Duan, W.; Li, X.; Shi, J.; Guo, Y.; Li, Z.; Li, C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience 2010, 169, 1621-1629.
106. Hashimoto, M.; Hsu, L.J.; Xia, Y.; Takeda, A.; Sisk, A.; Sundsmo, M.; Masliah, E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999, 10, 717-721.
107. McNaught, K.S.; Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 2001, 297, 191-194.
108. Deleidi, M.; Maetzler, W. Protein clearance mechanisms of alpha-synuclein and amyloid-beta in lewy body disorders. Int. J. Alzheimers Dis. 2012, 2012, 391-438.
109. Harry, G.J. Microglia during development and aging. Pharmacol. Ther. 2013, 139, 313-326.
110. Kanemoto, S.; Wang, H. Roles of endoplasmic reticulum stress in neurodegenerative diseases. Transl. Med. 2012, 2, 1000e108.
111. Bhandary, B.; Marahatta, A.; Kim, H.R.; Chae, H.J. An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases. Int. J. Mol. Sci. 2012, 14, 434-456.
112. Gardner, B.M.; Pincus, D.; Gotthardt, K.; Gallagher, C.M.; Walter, P. Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb. Perspect. Biol. 2013, 5, a013169.
113. Doyle, K.M.; Kennedy, D.; Gorman, A.M.; Gupta, S.; Healy, S.J.; Samali, A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J. Cell. Mol. Med. 2011, 15, 2025-2039.
114. Newton, H.B. Neurological complications of chemotherapy to the central nervous system. Handb. Clin. Neurol. 2012, 105, 903-916.
115. Van Dam, F.S.; Schagen, S.B.; Muller, M.J.; Boogerd, W.; Wall, E.; Droogleever Fortuyn, M.E.; Rodenhuis, S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standarddose chemotherapy. J. Natl. Cancer Inst. 1998, 90, 210-218.
116. Castellon, S.A.; Ganz, P.A.; Bower, J.E.; Petersen, L.; Abraham, L.; Greendale, G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 2004, 26, 955-969.
117. Vardy, J.; Wefel, J.S.; Ahles, T.; Tannock, I.F.; Schagen, S.B. Cancer and cancer therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Ann. Oncol. 2008, 91, 623-629.
118. Vardy, J.; Tannock, I. Cognitive function after chemotherapy in adults with solid tumours. Crit. Rev. Oncol. Hematol. 2007, 63, 183-202.
119. Joly, F.; Rigal, O.; Noal, S.; Giffard, B. Cognitive dysfunction and cancer: Which consequences in terms of disease management? Psychooncology 2011, 20, 1251-1258.
120. Schagen, S.B.; Muller, M.J.; Boogerd, W.; Mellenbergh, G.J.; van Dam, F.S. Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. J. Natl. Cancer Inst. 2006, 98, 1742-1745.
121. Ahles, T.A.; Saykin, A.J.; McDonald, B.C.; Li, Y.; Furstenberg, C.T.; Hanscom, B.S.; Mulrooney, T.J., Schwartz, G.N.; Kaufman, P.A. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J. Clin. Oncol. 2010, 28, 4434-4440.
122. Kreukels, B.P.; Schagen, S.B.; Ridderinkhof, K.R.; Boogerd, W.; Hamburger, H.L.; Muller, M.J.; van Dam, F.S. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin. Breast Cancer 2006, 7, 67-78.
123. De Ruiter, M.B.; Reneman, L.; Boogerd, W.; Veltman, D.J.; van Dam, F.S.; Nederveen, A.J.; Boven, E.; Schagen, S.B. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum. Brain Mapp. 2011, 32, 1206-1219.
124. Ahles, T.A.; Saykin, A.J.; McDonald, B.C.; Furstenberg, C.T.; Cole, B.F.; Hanscom, B.S.; Mulrooney, T.J.; Schwartz, G.N.; Kaufman, P.A. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res. Treat. 2008, 110, 143-152.
125. Wefel, J.S.; Saleeba, A.K.; Buzdar, A.U.; Meyers, C.A. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010,116, 3348-3356.
126. Tangpong, J.; Cole, M.P.; Sultana, R.; Joshi, G.; Estus, S.; Vore, M.; St Clair, W.; Ratanachaiyavong, S.; St Clair, D.K.; Butterfield, D.A. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol. Dis. 2006, 23, 127-139.
127. Joshi, G.; Hardas, S.; Sultana, R.; St Clair, D.K.; Vore, M.; Butterfield, D.A. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J. Neurosci. Res. 2007, 85, 497-503.
128. Seigers, R.; Timmermans, J.; van der Horn, H.J.; de Vries, E.F.; Dierckx, R.A.; Visser, L.; Schagen, S.B.; van Dam, F.S.; Koolhaas, J.M.; Buwalda, B. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav. Brain Res. 2010, 207, 265-272.
129. Seigers, R.; Schagen, S.B.; Beerling, W.; Boogerd, W.; van Tellingen, O.; van Dam, F.S.; Koolhaas, J.M.; Buwalda, B. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav. Brain Res. 2008, 186, 168-175.
130. Mustafa, S.; Walker, A.; Bennett, G.; Wigmore, P.M. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur. J. Neurosci. 2008, 28, 323-330.
131. Madhyastha, S.; Somayaji, S.N.; Rao, M.S.; Nalini, K.; Bairy, K.L. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can. J. Physiol. Pharmacol. 2002, 80, 1076-1084.
132. Seigers, R.; Fardell, J.E. Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neurosci. Biobehav. Rev. 2011, 35, 729-741.
133. Antioxidant Supplementation in Cancer: Potential Interactions with Conventional Chemotherapy and Radiation Therapy. Available online: http://jdc.jefferson.edu/jmbcim/12/ (accessed on 1 May 2001).
134. Pirzada, N.A.; Ali, I.I.; Dafer, R.M. Fluorouracil-induced neurotoxicity. Ann. Pharmacother. 2000, 34, 35-38.
135. Han, R.; Yang, Y.M.; Dietrich, J.; Luebke, A.; Mayer-Pröschel, M.; Noble, M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J. Biol. 2008, 7, 12.
136. Lamberti, M.; Porto, S.; Marra, M.; Zappavigna, S.; Grimaldi, A.; Feola, D.; Pesce, D.; Naviglio, S.; Spina, A.; Sannolo, N.; et al. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J. Exp. Clin. Cancer Res. 2012, 31, 60.
137. Baba, Y.; Sonoda, J.I.; Hayashi, S.; Tosuji, N.; Sonoda, S.; Makisumi, K.; Nakajo, M. Reduction of oxidative stress in liver cancer patients by oral green tea polyphenol tablets during hepatic arterial infusion chemotherapy. Exp. Ther. Med. 2012, 4, 452-458.
138. Numazawa, S.; Sugihara, K.; Miyake, S.; Tomiyama, H.; Hida, A.; Hatsuno, M.; Yamamoto, M.; Yoshida, T. Possible involvement of oxidative stress in 5-fluorouracil-mediated myelosuppression in mice. Basic Clin. Pharmacol. Toxicol. 2011, 108, 40-45.
139. Miketova, P.; Kaemingk, K.; Hockenberry, M.; Pasvogel, A.; Hutter, J.; Krull, K.; Moore, I.M. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. Biol. Res. Nurs. 2005, 6, 187-195.
140. Caron, J.E.; Krull, K.R.; Hockenberry, M.; Jain, N.; Kaemingk, K.; Moore, I.M. Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. Pediatr. Blood Cancer 2009, 53, 551-556.
141. Hildebrand, J. Neurological complications of cancer chemotherapy. Curr. Opin. Oncol. 2006, 18, 321-324.
142. NCI Report. Available online: http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2010/022310/page6 (accessed on 30 September 2013).
143. Postma, T.J.; Aaronson, N.K.; Heimans, J.J.; Muller, M.J.; Hildebrand, J.G.; Delattre, J.Y.; Hoang-Xuan, K.; Lantéri-Minet, M.; Grant, R.; Huddart, R.; et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur. J. Cancer 2005, 41, 1135-1139.
144. Tofthagen, C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs. 2010, 14, E22-E28.
145. Raffa, R.B.; Tallarida, R.J. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced "chemo-fog". J. Clin. Pharm. Ther. 2010, 35, 249-255.
146. Jonas, C.R.; Puckett, A.B.; Jones, D.P.; Griffith, D.P.; Szeszycki, E.E.; Bergman, G.F.; Furr, C.E.; Tyre, C.; Carlson, J.L.; Galloway, J.R.; et al. Plasma antioxidant status after high-dose chemotherapy: A randomized trial of parenteral nutrition in bone marrow transplantation patients. Am. J. Clin. Nutr. 2000, 72, 181-189.
147. Di Cesare Mannelli, L.; Zanardelli, M.; Failli, P.; Ghelardini, C. Oxaliplatin-induced neuropathy: Oxidative stress as pathological mechanism. Protective effect of silibinin. J. Pain 2012, 13, 276-284.
148. Valério, D.A.; Georgetti, S.R.; Magro, D.A.; Casagrande, R.; Cunha, T.M.; Vicentini, F.T.; Vieira, S.M.; Fonseca, M.J.; Ferreira, S.H.; Cunha, F.Q.; et al. Quercetin reduces inflammatory pain: Inhibition of oxidative stress and cytokine production. J. Nat. Prod. 2009, 72, 1975-1979.
149. Jiang, Y.; Guo, C.; Vasko, M.R.; Kelley, M.R. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 2008, 68, 6425-6434.
150. Minami, S.B.; Sha, S.H.; Schacht, J. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear. Res. 2004, 198, 137-143.
151. Waissbluth, S.; Daniel, S.J. Cisplatin-induced ototoxicity: Transporters playing a role in cisplatin toxicity. Hear. Res. 2013, 299, 37-45.
152. Rahman, K. Studies on free radicals, antioxidants, and co-factors. Clin. Interv. Aging 2007, 2, 219-236.
153. Conte, V.; Uryu, K.; Fujimoto, S.; Yao, Y.; Rokach, J.; Longhi, L.; Trojanowski, J.Q.; Lee, V.M.; McIntosh, T.K.; Praticò, D. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem. 2004, 90, 758-764.
154. Sung, S.; Yao, Y.; Uryu, K.; Yang, H.; Lee, V.M.; Trojanowski, J.Q.; Praticò, D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004, 18, 323-325.
155. Niki, E. Mechanisms and dynamics of antioxidant action of ubiquinol. Mol. Aspects Med. 1997, 18, S63-S70.
156. Yang, L.; Calingasan, N.Y.; Wille, E.J.; Cormier, K.; Smith, K.; Ferrante, R.J.; Beal, M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 109, 1427-1439.
157. Pandya, R.S.; Zhu, H.; Li, W.; Bowser, R.; Friedlander, R.M.; Wang, X. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2013, doi:10.1007/s00018-013-1415-0.
158. Gopal, K.V.; Wu, C.; Shrestha, B.; Campbell, K.C.; Moore, E.J.; Gross, G.W. d-Methionine protects against cisplatin-induced neurotoxicity in cortical networks. Neurotoxicol. Teratol. 2012, 34, 495-504.
159. Cloven, N.G.; Re, A.; McHale, M.T.; Burger, R.A.; DiSaia, P.J.; Rose, G.S.; Campbell, K.C.; Fan, H. Evaluation of D-methionine as a cytoprotectant in cisplatin treatment of an animal model for ovarian cancer. Anticancer Res. 2000, 20, 4205-4209.
160. Lorito, G.; Hatzopoulos, S.; Laurell, G.; Campbell, K.C.; Petruccelli, J.; Giordano, P.; Kochanek, K.; Sliwa, L.; Martini, A.; Skarzynski, H. Dose-dependent protection on cisplatin-induced ototoxicity-An electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model. Med. Sci. Monit. 2011, 17, BR179-BR186.
161. Gulec, M.; Oral, E.; Dursun, O.B.; Yucel, A.; Hacimuftuoglu, A.; Akcay, F.; Suleyman, H. Mirtazapine protects against cisplatin-induced oxidative stress and DNA damage in the rat brain. Psychiatry Clin. Neurosci. 2013, 67, 50-58.
162. Trevisan, G.; Materazzi, S.; Fusi, C.; Altomare, A.; Aldini, G.; Lodovici, M.; Patacchini, R.; Geppetti, P.; Nassini, R. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res. 2013, 73, 3120-3131.
163. CIPN: Treatment preservation and prevention are the goals. Available online: http://www.oncologynurseadvisor.com/cipn-treatment-preservation-and-prevention-are-the-goals/article/212533/ (accessed on 1 September 2011).
164. Carmody, R.J.; McGowan, A.J.; Cotter, T.G. Reactive oxygen species as mediators of photoreceptor apoptosis in vitro. Exp. Cell. Res. 1999, 248, 520-530.
165. Friesen, C.; Fulda, S.; Debatin, K.M. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ. 1999, 6, 471-480.
166. Kirkland, R.A.; Franklin, J.L. Evidence for redox regulation of cytochrome C release during programmed neuronal death: Antioxidant effects of protein synthesis and caspase inhibition. J. Neurosci. 2001, 21, 1949-1963.
167. Jiang, Z.G.; Lu, X.C.; Nelson, V.; Yang, X.; Pan, W.; Chen, R.W.; Lebowitz, M.S.; Almassian, B.; Tortella, F.C.; Brady, R.O.; et al. A multifunctional cytoprotective agent that reduces neurodegeneration after ischemia. Proc. Natl. Acad. Sci. USA 2006, 103, 1581-1586.
168. Kölker, S.; Ahlemeyer, B.; Krieglstein, J.; Hoffmann, G.F. Contribution of reactive oxygen species to 3-hydroxyglutarate neurotoxicity in primary neuronal cultures from chick embryo telencephalons. Pediatr. Res. 2001, 50, 76-82.
169. Shagirtha, K.; Muthumani, M.; Prabu, S.M. Melatonin abrogates cadmium induced oxidative stress related neurotoxicity in rats. Eur. Rev. Med. Pharmacol. Sci. 2011, 15, 1039-1050.
170. Boullerne, A.I.; Nedelkoska, L.; Benjamins, J.A. Synergism of nitric oxide and iron in killing the transformed murine oligodendrocyte cell line N20.1. J. Neurochem. 1999, 72, 1050-1060.
171. López-López, G.; Moreno, L.; Cogolludo, A.; Galisteo, M.; Ibarra, M.; Duarte, J.; Lodi, F.; Tamargo, J.; Perez-Vizcaino, F. Nitric oxide (NO) scavenging and NO protecting effects of quercetin and their biological significance in vascular smooth muscle. Mol. Pharmacol. 2004, 65, 851-859.
172. Zhang, Z.J.; Cheang, L.C.; Wang, M.W.; Lee, S.M. Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. Int. J. Mol. Med. 2011, 27, 195-203.
173. Hooper, D.C.; Scott, G.S.; Zborek, A.; Mikheeva, T.; Kean, R.B.; Koprowski, H.; Spitsin, S.V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 2000, 14, 691-698.
174. Kim, J.Y.; Jung, K.J.; Choi, J.S.; Chung, H.Y. Hesperetin: A potent antioxidant against peroxynitrite. Free Radic. Res. 2004, 38, 761-769.
175. Bass, D.A.; Parce, J.W.; Dechatelet, L.R.; Szejda, P.; Seeds, M.C.; Thomas, M. Flow cytometric studies of oxidative product formation by neutrophils: A graded response to membrane stimulation. J. Immunol. 1983, 130, 1910-1917.
176. Royall, J.A.; Ischiropoulos, H. Evaluation of 2',7'-dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2 in cultured endothelial cells. Arch. Biochem. Biophys. 1993, 302, 348-355.
177. Rao, K.M.; Padmanabhan, J.; Kilby, D.L.; Cohen, H.J.; Currie, M.S.; Weinberg, J.B. Flow cytometric analysis of nitric oxide production in human neutrophils using dichlorofluorescein diacetate in the presence of a calmodulin inhibitor. J. Leukoc. Biol. 1992, 51, 496-500.
178. Myhre, O.; Andersen, J.M.; Aarnes, H.; Fonnum, F. Evaluation of the probes 2',7'-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem. Pharmacol. 2003, 65, 1575-1582.
179. Keller, A.; Mohamed, A.; Dröse, S.; Brandt, U.; Fleming, I.; Brandes, R.P. Analysis of dichlorodihydrofluorescein and dihydrocalcein as probes for the detection of intracellular reactive oxygen species. Free Radic. Res. 2004, 38, 1257-1267.
180. Buxser, S.E.; Sawada, G.; Raub, T.J. Analytical and numerical techniques for evaluation of free radical damage in cultured cells using imaging cytometry and fluorescent indicators. Methods Enzymol. 1999, 300, 256-275.
181. Benov, L.; Sztejnberg, L.; Fridovich, I. Critical evaluation of the use of hydroethidine as a measure of superoxide anion radical. Free Radic. Biol. Med. 1998, 25, 826-831.
182. Kohli, R.; Pan, X.; Malladi, P.; Wainwright, M.S.; Whitington, P.F. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J. Biol. Chem. 2007, 282, 21327-21336.
183. Kalyanaraman, B. Oxidative chemistry of fluorescent dyes: Implications in the detection of reactive oxygen and nitrogen species. Biochem. Soc. Trans. 2011, 39, 1221-1225.
184. Kalyanaraman, B.; Dranka, B.P.; Hardy, M.; Michalski, R.; Zielonka, J. HPLC-based monitoring of products formed from hydroethidine-based fluorogenic probes-The ultimate approach for intra- and extracellular superoxide detection. Biochim. Biophys. Acta 2013, doi:10.1016/j.bbagen.2013.05.008.
185. Daiber, A.; Oelze, M.; August, M.; Wendt, M.; Sydow, K.; Wieboldt, H.; Kleschyov, A.L.; Munzel, T. Detection of superoxide and peroxynitrite in model systems and mitochondria by the luminol analogue L-012. Free Radic. Res. 2004, 38, 259-269.
186. Faulkner, K.; Fridovich, I. Luminol and lucigenin as detectors for O2. Free Radic. Biol. Med. 1993, 15, 447-451.
187. Spasojevic, I.; Liochev, S.I.; Fridovich, I. Lucigenin: Redox potential in aqueous media and redox cycling with O2 production. Arch. Biochem. Biophys. 2000, 373, 447-450.
188. Liochev, S.I.; Fridovich, I. Lucigenin as mediator of superoxide production: Revisited. Free Radic. Biol. Med. 1998, 25, 926-928.
189. Li, Y.; Zhu, H.; Kuppusamy, P.; Roubaud, V.; Zweier, J.L.; Trush, M.A. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J. Biol. Chem. 1998, 273, 2015-2023.
190. Zhao, H.; Joseph, J.; Fales, H.M.; Sokoloski, E.A.; Levine, R.L.; Vasquez-Vivar, J.; Kalyanaraman, B. Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. Proc. Natl. Acad. Sci. USA 2005, 102, 5727-5732.
191. Kruk, I.; Bozdaǧ-Dündar, O.; Ertan, R.; Aboul-Enein, H.Y.; Michalska, T. Hydroxyl and superoxide radical scavenging abilities of chromonyl-thiazolidine-2,4-dione compounds. Luminescence 2009, 24, 96-101.
192. Berczyński, P.; Kładna, A.; Kruk, I.; Piechowska, T.; Aboul-Enein, H.Y.; Bozdaǧ-Dündar, O.; Ceylan-Unlusoy, M. Antioxidant activities of some new chromonyl-2,4-thiazolidinediones and chromonyl-2,4-imidazolidinediones having chromone cores. J. Fluoresc. 2013, 23, 1319-1327.
193. Han, J.Y.; Takeshita, K.; Utsumi, H. Noninvasive detection of hydroxyl radical generation in lung by diesel exhaust particles. Free Radic. Biol. Med. 2001, 30, 516-525.
194. Utsumi, H.; Yamada, K. In vivo electron spin resonance-computed tomography/nitroxyl probe technique for non-invasive analysis of oxidative injuries. Arch. Biochem. Biophys. 2003, 416, 1-8.
195. Halliwell, B.; Whiteman, M. Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean? Br. J. Pharmacol. 2004, 142, 231-255.
196. Kojima, H.; Nakatsubo, N.; Kikuchi, K.; Kawahara, S.; Kirino, Y.; Nagoshi, H.; Hirata, Y.; Nagano, T. Detection and imaging of nitric oxide with novel fluorescent indicators: Diaminofluoresceins. Anal. Chem. 1998, 70, 2446-2453.
197. Nakatsubo, N.; Kojima, H.; Kikuchi, K.; Nagoshi, H.; Hirata, Y.; Maeda, D.; Imai, Y.; Irimura, T.; Nagano, T. Direct evidence of nitric oxide production from bovine aortic endothelial cells using new fluorescence indicators: diaminofluoresceins. FEBS Lett. 1998, 427, 263-266.
198. Curtin, J.F.; Donovan, M.; Cotter, T.G. Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods 2002, 265, 49-72.
199. Ueno, T.; Urano, Y.; Kojima, H.; Nagano, T. Mechanism-based molecular design of highly selective fluorescence probes for nitrative stress. J. Am. Chem. Soc. 2006, 128, 10640-10641.
200. Zielonka, J.; Sikora, A.; Joseph, J.; Kalyanaraman, B. Peroxynitrite is the major species formed from different flux ratios of co-generated nitric oxide and superoxide: Direct reaction with boronate-based fluorescent probe. J. Biol. Chem. 2010, 285, 14210-14216.
201. Bredt, D.S.; Snyder, S.H. Isolation of nitric oxide synthetase, a calmodulinrequiring enzyme. Proc. Natl. Acad. Sci. USA 1990, 87, 682-685.
202. Mayer, B.; Klatt, P.; Werner, E.R.; Schmidt, K. Molecular mechanisms of inhibition of porcine brain nitric oxide synthase by the antinociceptive drug 7-nitroindazole. Neuropharmacology 1994, 33, 1253-1259.
203. Ghafourifar, P.; Richter, C. Nitric oxide synthase activity in mitochondria. FEBS Lett. 1997, 418, 291-296.
204. Oda, T.; Sadakata, N.; Komatsu, N.; Muramatsu, T. Specific efflux of glutathione from the basolateral membrane domain in polarized MDCK cells during ricin-induced apoptosis. J. Biochem. 1999, 126, 715-721.
205. Franco, R.; Cidlowski, J.A. Glutathione efflux and cell death. Antioxid. Redox Signal. 2012, 17, 1694-1713.
206. Kosower, E.M.; Kosower, N.S. Bromobimane probes for thiols. Methods Enzymol. 1995, 251, 133-148.
207. Kaul, N.; Choi, J.; Forman, H.J. Transmembrane redox signaling activates NF-kappaB in macrophages. Free Radic. Biol. Med. 1998, 24, 202-207.
208. Tietze, F. Enzymatic method for quantification of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal. Biochem. 1969, 27, 502-522.
209. Li, Y.; Maher, P.; Schubert, D. Requirement for cGMP in nerve cell death caused by glutathione depletion. J. Cell Biol. 1997, 139, 1317-1324.
210. Peskin, A.V.; Winterbourn, C.C. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin. Chim. Acta 2000, 293, 157-166.
211. Esposito, L.; Raber, J.; Kekonius, L.; Yan, F.; Yu, G.Q.; Bien-Ly, N.; Puoliväli, J.; Scearce-Levie, K.; Masliah, E.; Mucke, L. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26, 5167-5179.
212. Fujita, H.; Fujishima H.; Chida, S.; Takahashi, K.; Qi, Z.; Kanetsuna, Y.; Breyer, M.D.; Harris, R.C.; Yamada, Y.; Takahashi, T. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J. Am. Soc. Nephrol. 2009, 20, 1303-1313.
213. Rousar, T.; Kucera, O.; Kriváková, P.; Lotková, H.; Kandár, R.; Muzáková, V.; Cervinková, Z. Evaluation of oxidative status in acetaminophen treated rat hepatocytes in culture. Physiol. Res. 2009, 58, 239-246.
214. Zemlan, F.P.; Thienhaus, O.J.; Bosmann, H.B. Superoxide dismutase activity in Alzheimer's disease: Possible mechanism for paired helical filament formation. Brain Res. 1989, 476, 160-162.
215. Pappolla, M.A.; Omar, R.A.; Kim, K.S.; Robakis, N.K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol. 1992, 140, 621-628.
216. Cohen, S.M.; Olin, K.L.; Feuer, W.J.; Hjelmeland, L.; Keen, C.L.; Morse, L.S. Low glutathione reductase and peroxidase activity in age-related macular degeneration. Br. J. Ophthalmol. 1994, 78, 791-794.
217. Paglia, D.E.; Valentine, W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967, 70, 158-69.
218. Braidy, N.; Selvaraju, S.; Essa, M.M.; Vaishnav, R.; Al-Adawi, S.; Al-Asmi, A.; Al-Senawi, H.; Abd Alrahman Alobaidy, A.; Lakhtakia, R.; Guillemin, G.J. Neuroprotective effects of a variety of pomegranate juice extracts against MPTP-induced cytotoxicity and oxidative stress in human primary neurons. Oxid. Med. Cell. Longev. 2013, 2013, 685-909.
219. Johansson, L.H.; Borg, L.A. A spectrophotometric method for determination of catalase activity in small tissue samples. Anal. Biochem. 1988, 174, 331-336.
220. Reinholz, M.M.; Haggard, J.J.; Curran, G.L.; Poduslo, J.F. Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood-brain barrier of putrescine-modified catalase in the adult rat. Exp. Neurol. 1999, 159, 191-203.
221. Kraus, R.L.; Pasieczny, R.; Lariosa-Willingham, K.; Turner, M.S.; Jiang, A.; Trauger, J.W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 2005, 94, 819-827.
222. Banerjee, S.; Chanda, A.; Ghoshal, A.; Debnath, R.; Chakraborty, S.; Saha, R.; Das, A. Nitric Oxide scavenging activity study of ethanolic extracts of Ixora coccinea from two different areas of kolkata. Asian J. Exp. Biol. Sci. 2011, 2, 595-599.
223. Noda, Y.; Mori, A.; Liburdy, R.; Packer, L. Melatonin and its precursors scavenge nitric oxide. J. Pineal Res. 1999, 27, 159-163.
224. Králová, J.; Pekarová, M.; Drábiková, K.; Jančinová, V.; Nosáľ, R.; Cíž, M.; Lojek, A. The effects of dithiaden on nitric oxide production by RAW 264.7 cells. Interdiscip. Toxicol. 2008, 1, 214-217.
225. Lang, J.; Celotto, C.; Esterbauer, H. Quantitative determination of the lipid peroxidation product 4-hydroxynonenal by high-performance liquid chromatography. Anal. Biochem. 1985, 150, 369-378.
226. Goldring, C.; Casini, A.F.; Maellaro, E.; Del Bello, B.; Comporti, M. Determination of 4-hydroxynonenal by high-performance liquid chromatography with electrochemical detection. Lipids 1993, 8, 141-145.
227. Fucile, C.; Marini, V.; Zuccoli, M.L.; Leone, S.; Robbiano, L.; Martelli, A.; Mattioli, F. HPLC determination of malondialdehyde as biomarker for oxidative stress: application in patients with alcohol dependence. Clin. Lab. 2013, 59, 837-841.
228. Yoritaka, A.; Hattori, N.; Uchida, K.; Tanaka, M.; Stadtman, E.R.; Mizuno, Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 1996, 93, 2696-2701.
229. Nelson, V.M.; Dancik, C.M.; Pan, W.; Jiang, Z.G.; Lebowitz, M.S.; Ghanbari, H.A. PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J. Alzheimers Dis. 2009, 17, 611-619.
230. Zitnanová, I.; Sumegová, K.; Simko, M.; Maruniaková, A.; Chovanová, Z.; Chavko, M.; Duracková, Z. Protein carbonyls as a biomarker of foetal-neonatal hypoxic stress. Clin. Biochem. 2007, 40, 567-570.
231. Yang, H.; Zhang, Y.; Pöschl, U. Quantification of nitrotyrosine in nitrated proteins. Anal. Bioanal. Chem. 2010, 397, 879-886.
232. Valavanidis, A.; Vlachogianni, T.; Fiotakis, C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health C 2009, 27, 120-139.
233. Hofer, T.; Seo, A.Y.; Prudencio, M.; Leeuwenburgh, C. A method to determine RNA and DNA oxidation simultaneously by HPLC-ECD: Greater RNA than DNA oxidation in rat liver after doxorubicin administration. Biol. Chem. 2006, 387, 103-111.
234. Ohshima, H.; Sawa, T.; Akaike, T. 8-nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species: formation, occurrence, and implications in inflammation and carcinogenesis. Antioxid. Redox Signal. 2006, 8, 1033-1045.
235. Sawa, T.; Tatemichi, M.; Akaike, T.; Barbin, A.; Ohshima, H. Analysis of urinary 8-nitroguanine, a marker of nitrative nucleic acid damage, by high-performance liquid chromatography-electrochemical detection coupled with immunoaffinity purification: Association with cigarette smoking. Free Radic. Biol. Med. 2006, 40, 711-720.
236. Halliwell, B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett. 1997, 411, 157-160.
237. Tsikas, D.; Caidahl, K. Recent methodological advances in the mass spectrometric analysis of free and protein-associated 3-nitrotyrosine in human plasma. J. Chromatogr. B 2005, 814, 1-9.